Efficacy and tolerability of pramipexole for the treatment of primary restless leg syndrome: a meta-analysis of randomized placebo-controlled trials
Authors:
- Ye WangYWYe Wang
- Shu Yan CongSCShu Yan Cong
- Jian Fei NaoJNJian Fei Nao
- Juan FengJFJuan Feng
- Guo Rong BiGBGuo Rong Bi
Open Access
- 1 July 2013
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 9, 1035-1043
Abstract
Primary restless leg syndrome (RLS) is a common sensory-motor disorder that is characterized by an irresistible urge to move the limbs and unpleasant sensations in the legs, which affects 1.9%–4.6% adults. Pramipexole, a potent dopamine D2/3 agonist, is recommended as “effective” in the short-term and “possibly effective” in the long-term treatment of primary RLS in the European guidelines on management of RLS. In this meta-analysis, we summarized the efficacy and tolerability of pramipexole in treatment for primary RLS. Results of this meta-analysis showed a favorable effect of pramipexole versus placebo on RLS symptoms (mean change on International RLS Study Group Rating Scale [IRLS] score: mean difference [MD] = -5.96; 95% confidence interval [CI]: -7.79 to -4.41, P < 0.00001) and sleep quality (pooled standard mean difference [SMD] = -0.48, 95% CI: -0.61 to -0.35, P < 0.00001). Nausea (relative risk [RR] = 2.68, 95% CI: 1.82 to 3.95, P < 0.001) and fatigue (RR = 1.82, 95% CI: 1.14 to 2.93, P = 0.013) were the most common adverse events, but, by and large, pramipexole was well-tolerated in patients with primary RLS. Nevertheless, long-term studies and more evidence of head-to-head comparisons of pramipexole with other dopamine agonists, anticonvulsants, and levodopa are needed.Keywords
This publication has 19 references indexed in Scilit:
- Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trialSleep Medicine, 2012
- Dopamine agonists for the treatment of restless legs syndromeCochrane Database of Systematic Reviews, 2011
- The PRISMA Statement: A Guideline for Systematic Reviews and Meta-AnalysesJournal of Pediatric Health Care, 2011
- Intention-to-treat concept: A reviewPerspectives in Clinical Research, 2011
- Restless legs syndrome: pathophysiology, clinical presentation and managementNature Reviews Neurology, 2010
- Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled studySleep Medicine, 2010
- Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndromeSleep Medicine, 2008
- Efficacy of pramipexole in restless legs syndrome: A six‐week, multicenter, randomized, double‐blind study (effect‐RLS study)Movement Disorders, 2006
- The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG)Sleep Medicine, 2006
- Restless legs syndrome: diagnostic criteria, special considerations, and epidemiologySleep Medicine, 2003